In this episode of IP+ with Knobbe Martens, Jeremiah Helm, Co-Chair of Knobbe Martens’ Appellate Litigation practice, and Carol Pitzel Cruz, Co-Chair of the firm’s Hatch-Waxman Litigation practice, discuss one of the most consequential IP cases so far this year: the recent SCOTUS ruling in Hikma v. Amarin. In their discussion, Jeremiah and Carol break down the main issues at play in the ANDA litigation case, including generic drug manufacturers’ use of skinny labels, the nuances of induced infringement, and why the decision may reverberate beyond the pharmaceutical industry.
Listen to the episode below or read the full transcript here.
About Knobbe IP+
Knobbe Martens proudly presents the Knobbe IP+ Podcast, featuring thoughtful and engaging conversations with the people at the forefront of intellectual property. Download and listen to the latest episodes for unique insights and perspectives on the developments and trends driving IP today. Knobbe IP+ episodes are available on Apple Podcasts, Spotify, and anywhere podcasts can be found.
Subscribe for News and Updates
